Adagene Inc.

NASDAQ:ADAG

Biotechnology

Healthcare
$1.82 +3.68%

+$0.13 today

Market cap
$68.52M
Beta
0.59
P/E (TTM)
-7.9
EPS (TTM)
-$0.47
52W Low $1.30High $4.75

Volume 1.30M

Average 0.21M

ADAG Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Adagene Inc.NASDAQ: ADAG

Weighted Avg Shares (Diluted) · Q4 FY2025 · quarter ended Dec 2025

Weighted avg shares (diluted) grows in line with its trailing trend

Q4 FY2025 weighted avg shares (diluted) of 37.91M shares rose 3.3% year over year, ahead of the +1.6% change in trailing-twelve-month weighted avg shares (diluted). Over 3 fiscal years it compounded at +2.9% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3.3% holds above the trailing-twelve-month pace of +1.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
37.91M— QoQ
Last fiscal yearDec 2025
37.76M+4.8% YoY
LTMJun 2024
35.23M+1.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.3%——
1 year+4.8%——
3-year CAGR+2.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
37.76M USD
Year-over-year change
+4.8%
4-year CAGR
+4.2%

Weighted Avg Shares (Diluted) vs competitors

How ADAG compares with its peers on the latest reported figures

  • ADAG's LTM Jun 2024 weighted avg shares (diluted) of 35.23M shares is the 3rd highest of the 9 companies compared; the peer median is 30.87M shares.
  • Over three fiscal years its annual growth of +2.9% compares with a peer median of +25.1%.
ADAG Competitors Peer median
Weighted Avg Shares (Diluted) for ADAG and competitors
Company Period LTM YoY 3-year CAGR
TCRXTScan Therapeutics, Inc.LTM Mar 2026129.84M +7.6%+75.4%
FBIOFortress Biotech, Inc.LTM Mar 202695.09M +349.0%+261.1%
ADAGAdagene Inc.LTM Jun 202435.23M —+2.9%
GANXGain Therapeutics, Inc.LTM Mar 202635.13M +38.4%+40.5%
OSTXOS Therapies IncorporatedLTM Mar 202631.25M -31.1%+8.2%
XBITXBiotech Inc.LTM Mar 202630.49M +0.1%+0.1%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202626.06M +115.3%-31.2%
NTRBNutriband Inc.LTM Apr 202611.9M +8.4%+11.2%
ACETAdicet Bio, Inc.LTM Mar 20267.26M +28.8%+39.0%
Peer median (excluding ADAG) 30.87M+18.6%+25.1%

Competitors are the stored peer set for ADAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.18M9.29M18.11M103.2K7.67M
Cost of Revenue00000
Gross Profit10.18M9.29M18.11M(823.04K)7.67M
Gross Margin100.0%100.0%100.0%-797.5%100.0%
Research & Development68.1M81.34M36.64M28.78M22.03M
Selling, General & Admin14.44M11.87M8.67M7.27M7.08M
Operating Expenses82.54M93.21M41.83M36.05M29.11M
Depreciation & Amortization1.13M1.43M1.21M926.25K589.79K
EBITDA(69.99M)(77.39M)(14.95M)(31.66M)(16.85M)
EBITDA Margin-687.8%-832.8%-82.5%-30680.5%-219.7%
Operating Income(72.36M)(83.92M)(23.72M)(35.95M)(21.44M)
Operating Margin-711.2%-903.1%-131.0%-34835.4%-279.5%
Interest Income76.17K377.5K4.28M3.8M2.3M
Interest Expense363.76K693.32K1.11M851.87K463.13K
Other Income / Expenses887.77K4.41M6.46M2.51M3.53M
Income Before Tax(71.48M)(79.51M)(17.25M)(33.44M)(17.91M)
Pre-Tax Margin-702.5%-855.6%-95.3%-32403.5%-233.4%
Income Tax Expense1.7M459.06K1.69M(17.55K)(297.86K)
Net Income(73.18M)(79.97M)(18.95M)(33.42M)(17.61M)
Net Margin-719.2%-860.6%-104.6%-32386.4%-229.6%
EPS (Basic)(2.29)(2.31)(0.55)(0.95)(0.46)
EPS (Diluted)(2.29)(2.31)(0.54)(0.95)(0.46)
Weighted Avg Shares32.02M34.65M34.64M36.02M37.76M
Weighted Avg Shares (Diluted)32.02M34.65M35.03M36.02M37.76M

Adagene Inc.

NASDAQ:ADAG

Intrinsic Alpha fair value

Locked

Current Price

$1.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.